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Background: Little is known regarding the burden of opioid-induced constipation (OIC) 
among patients who suffer from cancer-related pain.
Methods: A prospective longitudinal study was conducted among cancer patients in 
the United Kingdom (UK), Canada, and Germany, which included medical record data 
abstraction, Internet-based patient surveys, and physician surveys. Patients on daily 
opioid therapy (≥30 mg for ≥4 weeks) for treatment of cancer pain with self-reported 
OIC were recruited. Response to laxatives was defined by classifying participants 
into categories of laxative use and evaluating the prevalence of inadequate response. 
Descriptive statistics were used to evaluate outcomes, including the patient assessment 
of constipation-symptom (PAC-SYM), patient assessment of constipation-quality of life, 
EuroQOL-5 dimensions, and global assessment of treatment benefit, satisfaction, and 
willingness to continue.
results: Recruitment was difficult for this study with only 31 participants completing 
the baseline survey and meeting criteria for opioid use and OIC (26 UK, 1 Canada, and 
4 Germany). Fifty-two percent (n = 16) of participants were male, and all were White. 
Breast (23%, n = 7), pancreatic (13%, n = 4), and multiple myeloma (13%, n = 4) were 
the most common cancers. Mean duration of chronic pain and opioid use were 2.3 and 
1.3 years, respectively. Participants reported having a mean of 4.4 bowel movements/
week in the 2  weeks prior to baseline, of which a mean of 0.9 were spontaneous. 
Most participants (90%, n =  28) were using at least 1 lifestyle approach to manage 
their constipation; 65% (n = 20) were taking ≥1 over-the-counter laxative; 19% (n = 6) 
were taking ≥1 prescription laxative; 23% (n = 7) reported no laxative use in the prior 
2 weeks. Moderate-to-severe constipation symptoms on the PAC-SYM were common, 
and mean scores on health-related quality of life outcomes were comparable to chronic 
pain populations.
conclusion: In this primarily UK sample, there appears to be considerable unmet OIC 
treatment needs among cancer patients.
Keywords: opioid, constipation, pain, laxatives, symptoms, cancer
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inTrODUcTiOn
At present, there is no consensus definition of opioid-induced 
constipation (OIC) to guide clinical and epidemiological research 
or to inform treatment recommendations (1). Depending on the 
study design and patient population, estimates of the prevalence 
of OIC range from 15 to 90% based on an analysis of 16 clinical 
trials and observational studies identified in a systematic review 
(2) and from 70 to 100% among hospitalized patients (3). The 
DYONISOS study (DYsfonctiONs Intestinales induiteS par 
les OpioıdS forts), a cross-sectional observational study con-
ducted among 520 patients with cancer pain in France found 
that 62% showed a degree of constipation that is problematic 
according to the patient-reported Knowles–Eccersley–Scott 
symptom (KESS) score (4). Even more patients (86%) were 
considered constipated according to physician’s subjective 
assessment – despite that 85% of these patients reported using 
laxatives regularly.
Little is known about the decision tree by which cancer patients 
and their physicians manage OIC. Available management options 
include lifestyle strategies, such as exercise, increased intake 
of fiber and fluids, and probiotics, followed by use of laxatives 
[both over-the-counter (OTC) and prescription treatments] (1). 
However, these strategies are often ineffective, and patients con-
tinue to experience substantial impact on their activities of daily 
living and overall health-related quality of life (HRQL) (5). Some 
patients have reported that they would rather endure their pain 
than continue with the constipating side effects associated with 
their opioid treatment (6, 7). Thus, OIC can impair adherence 
to opioid treatment, which can lead to increased morbidity and 
decreased HRQL in patients with cancer.
In order to better understand OIC among cancer patients, a 
hybrid, prospective longitudinal study was designed to generate 
real-world empirical evidence of the patient burden and experi-
ence of OIC. Difficulties were encountered when recruiting sites 
and patients with cancer pain. The recruitment for this patient 
cohort was truncated after 13  months where 31 patients were 
enrolled. The objective of this paper is to present the completed 
baseline data to characterize demographics, clinical characteris-
tics, constipation symptoms, pain management, OIC treatments, 
rate of inadequate response to laxatives, and the impact of OIC on 
HRQL in this small convenience sample of patients with cancer 
pain and OIC.
MaTerials anD MeThODs
study Design
This analysis focuses on baseline data from a patient survey con-
ducted among patients with cancer pain and is part of an ongoing 
longitudinal study evaluating clinical characteristics and burden 
of OIC among patients with cancer and non-cancer pain using 
a combination of patient surveys, retrospective data abstraction 
from medical records, and physician surveys (8, 9).
The study received institutional review board approval and was 
executed in accordance with the Canadian regulation known as 
the Personal Information Protection and Electronic Documents 
Act, Health Insurance Portability and Accountability Act of 1996, 
European Union Data Protection Directive, and Safe Harbor 
agreement. The protocol (NCT01928953) was also reviewed and 
endorsed by the Anesthetics Pain Subgroup and the Primary Care 
Research Network.
The Internet-based patient-reported component includes the 
baseline survey and eight follow-up Internet surveys conducted 
over 24 weeks (Weeks 2, 4, 6, 8, 12, 16, 20, and 24). The retro-
spective chart review was completed by the clinical sites via the 
Internet at baseline and again at the end of the study period 
(Week 24) for each patient who completed a baseline survey. The 
Internet-based patient-specific physician survey was completed 
at baseline and at Week 24 for each patient who completed the 
baseline survey. Data from the chart review and physician survey 
are still being collected.
study sample and Data collection
Additional details about participant recruitment and data 
 collection procedures are described elsewhere in the manuscript 
summarizing the study methodology and descriptive analysis of 
baseline study outcomes in the non-cancer pain study sample (8).
Briefly, participants were patients with cancer who were 
recruited from oncology clinics, primary care clinics, pain man-
agement clinics, and clinical research sites affiliated with primary 
care networks who had chart confirmation of daily opioid therapy 
lasting ≥4  weeks for the treatment of chronic cancer pain and 
who self-reported OIC during their screening interview. Clinical 
site staff identified a preliminary cohort of potentially eligible 
patients by review of the medical charts at their site. Staff then 
described the study and the informed consent process to each 
identified patient. Following completion of the baseline survey, 
participants were compensated for their time in the form of an 
electronic gift card in the country’s currency, with values ranging 
from the equivalent of 15 to 25 USD.
The initial recruitment target for cancer pain patients was 150 
patients. However, due to extensive difficulties in recruiting clini-
cal sites to recruit patients and in recruiting cancer pain patients 
to participate in this OIC burden of illness study, recruitment was 
truncated after 13 months with only 31 patients enrolled. No sites 
were activated in the US.
Patient Survey
The patient survey included demographic questions regarding 
gender, age, race, education, marital status, employment status, 
and insurance type. The survey also included questions about 
clinical characteristics, including rating of overall health, dura-
tion, type, and severity of chronic pain, and duration of opioid 
use including changes in opioid pain medications to have a bowel 
movement (BM).
Opioid-induced constipation status was confirmed during 
the survey by patients meeting one of the following criteria: 
responding “yes” to question “Since starting the opioid pain 
medication, have you been experiencing constipation or worsen-
ing of current constipation? Yes/No”; OR reporting fewer than 
three BMs per week, OR reporting laxative use if more than 
three BM per week, OR report at least one symptom of OIC on 
the patient assessment of constipation-symptom (PAC-SYM) in 
the past 2  weeks. Participants’ answered questions about their 
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history of constipation, including questions about the duration 
of constipation symptoms and health-care seeking in relation to 
constipation symptoms, as well as questions about which thera-
pies the health-care provider (HCP) suggested for constipation. 
Information about participants’ bowel symptoms, including BM 
frequency, spontaneity, and preferences, were collected in addi-
tion to which therapies they used to relieve their constipation. 
Management options included lifestyle approaches (probiotics, 
increased fluids, increased exercise, and natural diet change), 
OTC therapies (fiber supplements, stool softeners, and laxatives), 
and prescription laxatives.
The PAC-SYM questionnaire (10) was designed to assess the 
severity of patient-reported symptoms over the previous 2 weeks. 
The 12-item measure assesses three subscales: stool, rectal, and 
abdominal symptoms. Each item is rated on a five-point Likert 
scale, ranging from 0 to 4, where a higher score indicates greater 
symptom severity. The PAC-SYM has been widely used in OIC 
medication treatment studies and has performed as expected in 
relation to clinical outcomes (11–14). The PAC-SYM items and 
additional constipation symptoms, as well as the frequency of 
discomfort and degree of bother of each symptom, were collected 
at each survey completion.
Finally, participants also completed patient-reported question-
naires assessing condition-specific and general HRQL, including
 1. The patient assessment of constipation-quality of life (PAC-
QOL): a 28-item measure designed to capture four QOL 
domains: physical discomfort, psychological discomfort, wor-
ries and concerns, and satisfaction (which was not measured 
in this study) with a recall period of 2 weeks. Similar to the 
PAC-SYM, participants are asked to rate themselves over the 
previous 2 weeks on a five-point Likert scale ranging from 0 
to 4, where higher scores indicate worse QOL.
 2. The EuroQOL-5 dimensions (EQ-5D) is a five-item health state 
descriptive system where full health is 1 and 0 is equivalent to 
death (EQ-5D index), and a visual analog scale (EQ-5D VAS, 
range 0–100 from worst to best imaginable health state). There 
is extensive evidence supporting the reliability and validity of 
the EQ-5D (15), and it has performed well in a range of thera-
peutic areas, including OIC (16). The EQ-5D was completed 
by participants on-site in a paper-based format, and the data 
were entered into the Internet-based data capture system. 
Scoring was based on developer guidelines and weighted by 
country (15).
 3. The global assessment of treatment benefit, satisfaction, and 
willingness (BSW) to continue consists of three single-item 
measures that are designed to capture patients’ perception of 
the effect of their treatment in terms of benefits, satisfaction, 
and willingness to continue treatment (17). The BSW has 
demonstrated evidence of construct validity in patients with 
overactive bladder and has been used in urology treatment 
studies (17, 18) and the non-cancer pain sample (8).
statistical analysis
Analyses were performed using SAS version 9.4 (SAS Institute, 
Cary, NC, USA) following a statistical analysis plan approved 
prior to receipt of the locked and clean dataset. The data 
were analyzed as observed, without imputation for miss-
ing responses. Descriptive statistics were used to evaluate 
outcomes. For continuous variables, the mean and SD were 
described and rounded to one decimal for all data. For categori-
cal variables, the number and percent distribution by category 
were described.
Participants who completed the baseline survey were further 
evaluated for presence of OIC in order to confirm study eligibility, 
which included the following criteria.
Participants who responded “Yes” to the baseline question: 
“Since starting opioid pain medication, have you been experienc-
ing constipation or worsening of current constipation? Yes/No”; 
OR participants who reported laxative use if the number of BMs 
in the past 2 weeks is ≥3/week; OR participants who reported <3 
BMs/week in the past 2 weeks were eligible, regardless of whether 
they reported laxative use; OR participants who did not report 
laxative use but reported at least one symptom of OIC at least 
“moderate” or more often on the PAC-SYM screening questions 
in the past 2 weeks (i.e., incomplete BM, BM too hard, straining 
during BM, or sensation of false alarm).
Participants were classified into groups based on their use 
of laxatives, which included the following: stool softeners [e.g., 
docusate sodium (Colace®, Ducolax® stool softener), mineral oil], 
osmotics [e.g., polyethylene glycol 3350 (MiraLAX®, Dulcolax® 
balance)], stimulants [bisacodyl (Ducolax® laxative), senna 
(Senokot®, Exlax®)], salines [magnesium hydrochloride (Milk of 
Magnesia®, Citroma®)], rectal options (suppositories, enemas), 
and prescription therapies [polyethylene glycol 3350, lactulose 
(Constulose®), Lubiprostone (Amitiza®), and methylnaltrexone 
bromide (Relistor®)].
Sufficient laxative use was defined as use of at least one laxa-
tive ≥4 times over the last 2 weeks; insufficient laxative use was 
defined as use of at least one laxative <4 times but ≥1 time over 
the last 2 weeks, and non-laxative use was defined as no reported 
laxative use over the last 2 weeks. These categories were created 
to quantify laxative exposure in relation to other outcomes and 
do not imply clinical sufficiency.
resUlTs
Demographic and clinical characteristics
All 31 (100%) participants completing the baseline survey met 
criteria for opioid use and OIC. Eighty-four percent (N =  26) 
were from the United Kingdom (UK), 3% (N =  1) was from 
Canada, and 13% (N =  4) were from Germany. Just over half 
(n = 16, 52%) were male, and all were White (Table 1). Most were 
married (n = 28) and unable to work due to disability or handicap 
(n = 11) or retired (n = 16).
Most participants (n = 24) reported discussing their OIC with 
their HCP during an office visit (Table  2). The same propor-
tion reported that their doctor explained that constipation was 
a potential side effect of opioid treatment. Among participants 
who discussed their constipation symptoms with their HCP in 
the prior month, 85% reported their HCP offered helpful advice 
for treatment of their symptoms.
TaBle 2 | Patient-reported baseline clinical characteristics and pain.
Baseline 
(N = 31)
Discussed OIC with HCP during office visit (N, %)  
(N = 27 who had office visit)
24 (88.9)
Health rating (N, %)
Excellent 0 (0.0)
Very good 1 (3.2)
Good 4 (12.9)
Fair 13 (41.9)
Poor 13 (41.9)
Type of chronic pain (N, %)a
Pain related to cancer 30 (96.8)
Back pain 15 (48.4)
Joint pain 10 (32.3)
Pain syndrome 10 (32.3)
Neuralgia 3 (9.7)
Fibromyalgia 2 (6.5)
Rheumatoid arthritis 2 (6.5)
Headache or migraine 1 (3.2)
Otherb 2 (6.5)
Pain severity
Average pain last 24 h (mean, SD) 5.2 (2.5)
Average pain last 7 days (mean, SD) 5.2 (2.6)
How much does the constipation interfere with your ability of 
opioid medication to control pain? (N, %)
N = 28
No interference; pain adequately managed 5 (17.9)
Little interference, pain mostly managed 11 (39.3)
Moderate interference, pain moderately managed 11 (39.3)
Complete interference with adequate pain management; 
pain not at all managed
1 (3.6)
In the past 7 days, did you change how you used your opioid 
pain medication(s), so that you could have BMs? (n, % yes)
3 (9.7)
If yes: how change (N, %) N = 3
No longer take my pain medication 0 (0.0)
Reduced how much of my pain medication I use 2 (66.7)
Temporarily interrupted the use of pain medication 0 (0.0)
Switched to a different pain medication 0 (0.0)
Other 1 (33.3)
aThis category is not mutually exclusive, and participants were able to report more than 
one type of chronic pain.
bOther includes liver metastases (N = 1) and leg/ankle cramp (N = 1).
BM, bowel movement; HCP, health-care provider; OIC, opioid-induced constipation.
TaBle 1 | Participant demographics.
Baseline  
(N = 31)a
Gender (N, % male) 16 (51.6)
Age (mean, SD years) 60.7 (10.0)
Race (N, % White/Caucasian) 31 (100.0)
Marital status
Married 28 (90.3%)
Divorced 1 (3.2%)
Widowed 2 (6.5%)
Employment status
Employed, full-time 2 (6.5%)
Employed, part-time 1 (3.2%)
Unable to work due to disability or handicap 11 (35.5%)
Not currently working for pay (e.g., full-time 
homemaker)
1 (3.2%)
Retired 16 (51.6%)
aEligible population defined as all participants recruited into the study and who have 
baseline survey data, are on opioids per protocol, and met criteria for opioid-induced 
constipation.
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Most patients reported that their health was fair (n =  13) 
or poor (n  =  13). The mean (±SD) duration of pain was 
2.3 ± 3.6 years, and the mean (±SD) duration of opioid medica-
tion use was 1.3 ± 1.3 years. In addition to pain related to their 
cancer, patients commonly reported back pain (n =  15), joint 
pain (n = 10), and pain syndrome (n = 10). Many participants 
(n =  12) reported that their constipation moderately or com-
pletely interfered with the ability of their opioid medication to 
control pain.
Nearly, half (n =  15) were on more than one opioid, with 
morphine being the most frequently prescribed opioid (n = 13) 
followed by oxycodone (n = 12). The mean morphine equivalent 
dose (MED) at baseline was 183.3 ± 185 mg, and five patients had 
a MED of ≥200 mg/day. Nine patients discontinued use of their 
opioids over the course of the study and mean MED at week 24 
for remaining patients was 251.3 ± 313.4 mg.
constipation and Bowel symptoms
Participants reported 4.4 ± 2.5 BMs on average per week, with 
0.9 ± 1.5 BMs being spontaneous. Eighty-seven percent of par-
ticipants (n = 26) reported wanting to have a BM at least once a 
day or more. Thirty participants reported at least 1 of the 12 PAC-
SYM symptoms as moderate or greater in intensity (Table 3). Not 
only did these symptoms occur with moderate or greater severity 
but also the symptoms occurred frequently in at least 25% of each 
BM for most patients: discomfort in abdomen (n = 27), pain in 
abdomen (n = 24), bloating in abdomen (n = 23), painful BM 
(n = 21), incomplete BM (n = 22), BMs too hard (n = 19), strain-
ing/squeezing to pass BM (n = 22), and feeling like had to pass 
BM but could not (n = 19).
laxative Use
The most frequently utilized OIC management options in the 
past 2 weeks were natural or behavior therapies, including dietary 
changes, increased fluids or exercise, probiotics, and fiber sup-
plements (n = 28; Table 4). At least 1 OTC laxative, such as stool 
softeners, osmotic laxatives, saline laxatives, or rectal options, was 
used by 20 participants and 6 used 1 or more prescription agents. 
Over half of participants (n = 16) used a combination of at least 
one natural or behavioral therapy and one OTC therapy.
Twenty-two participants met the study criteria for sufficient 
laxative use, defined as use of at least one laxative four or more 
times over the past 2 weeks, two had insufficient laxative use, and 
seven reported no laxative use at all in the prior 2 weeks.
health-related Quality of life and 
Perceived Treatment Benefit
Patient-reported outcomes on the PAC-QOL, EQ-5D, and BSW 
reflected the considerable disease burden of this population. 
The mean (±SD) PAC-QOL physical discomfort, psychosocial 
discomfort, and worries and concerns domain scores were 
1.7 ± 1.0, 1.2 ± 1.1, 1.9 ± 1.1, respectively (Table 5). The mean 
(±SD) EQ-5D index score was 0.54 ± 0.28, and the mean (±SD) 
EQ-5D VAS score was 54.4 ± 16.3 (Table 5).
TaBle 5 | Pac-QOl and eQ-5D.
Baseline  
(N = 31)
PAC-QOL (mean, SD)a
Physical discomfort 1.7 (1.0)
Psychosocial discomfort 1.2 (1.1)
Worries and concerns 1.9 (1.1)
EQ-5D indexb N = 30
Mean (SD) 0.54 (0.28)
EQ-5D VASc N = 30
Mean (SD) 54.4 (16.3)
aScores range from 0 to 4 with lower scores indicating better quality of life.
bCountry-specific weights were used to calculate scores (15, 19). EQ-5D Index scores 
range from 0 (death) to 1 (full health).
cThe EQ-5D VAS ranges from 0 (“worst imaginable health state”) to 100 (“best 
imaginable health state”).
EQ-5D, EuroQol-5 dimension; VAS, visual analog scale.
TaBle 4 | summary of natural/behavioral therapies and laxative 
utilization for management of Oic.
Baseline  
(N = 31)
Use within each category (past 2 weeks)
Natural/behavioral approachesa (N, %)
≥1 28 (90.3)
≥2 17 (54.8)
≥3 9 (29.0)
OTC laxativesb (N, %)
≥1 20 (64.5)
≥2 8 (25.8)
≥3 2 (6.5)
Prescription agentsc (N, %)
≥1 6 (19.4)
≥2 2 (6.5)
≥3 1 (3.2)
Natural/behavioral approaches and laxative 
combinations (N, %)
Natural/behavioral approaches and OTC laxative 16 (51.6)
≥1 Natural/behavioral therapies only 6 (19.4)
≥1 OTC only 2 (6.5)
Natural/behavioral approaches, OTC laxative, and 
prescription agent
2 (6.5)
Natural/behavioral approaches and prescription agent 4 (12.9)
No natural/behavioral approach or laxative use 1 (3.2)
aIncludes probiotics, natural dietary changes, increased fluids, increased exercise, and 
fiber supplements.
bIncludes stool softeners, osmotic laxatives, saline laxatives, rectal options, and other 
OTC products.
cIncludes prescription osmotic laxatives, lactulose, Amitiza®, Relistor®, and other 
prescription agents.
OTC, over-the-counter.
TaBle 3 | Pac-sYM items and subscales and additional at least moderate 
constipation symptoms.
Baseline  
(N = 31)
Any symptom ≥ moderate present, N (%) 30 (96.8)
Discomfort abdomen, N (%) 23 (74.2)
Pain in abdomen, N (%) 20 (64.5)
Bloating in abdomen, N (%) 24 (77.4)
Stomach cramps, N (%) 14 (45.2)
Painful BM, N (%) 22 (71.0)
Rectal burning during or after BM, N (%) 12 (38.7)
Rectal bleeding/tearing during or after BM, N (%) 7 (22.6)
Incomplete BM, N (%) 16 (51.6)
BMs too hard, N (%) 18 (58.1)
BMs too small, N (%) 12 (38.7)
Straining/squeezing to pass BM, N (%) 17 (54.8)
Feeling like had to pass BM but could not, N (%) 16 (51.6)
Additional symptoms
Nausea, N (%) 4 (12.9)
Vomiting, N (%) 2 (6.5)
Flatulence, N (%) 20 (64.5)
Gastroesophageal reflux, N (%) 9 (29.0)
Headache or migraine, N (%) 2 (6.5)
BM, bowel movement; OIC, opioid-induced constipation; PAC-SYM, patient 
assessment of constipation symptoms.
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Twenty-three participants reported on the BSW questionnaire 
that they had some benefit from their treatment for constipation, 
with the majority of those who reported benefit characterizing it 
as “little” (n = 13, 57%; Table 6). Nonetheless, all but one partici-
pant reported being willing to continue their current treatment 
for constipation.
DiscUssiOn
This study was conducted to generate real-world empirical evi-
dence to inform medical understanding of the OIC burden and 
its management among patients with cancer pain. Participants 
commonly reported a range of constipation symptoms as assessed 
by the PAC-SYM. These findings contribute to the understand-
ing of the OIC experience by signaling some consistencies and 
a few notable inconsistencies when compared to our previously 
reported results conducted among the portion of the study sam-
ple with chronic non-cancer pain (20) despite the notable sample 
size discrepancy and lack of US presence in the cohort.
The prevalence of sufficient laxative use reported in this 
descriptive sample of cancer patients with OIC (n = 22, 71%) was 
higher than what was found among patients with OIC and non-
cancer pain (n = 234, 48%). This may be due to the higher rates of 
discussion regarding OIC between the physicians and patients in 
the cancer cohort (n = 24, 77%) than non-cancer cohort (n = 309, 
63%). Participants with cancer pain also reported a greater number 
of BMs per week on average (4.4) as compared to those with non-
cancer pain (3.7), though fewer of these were spontaneous (cancer 
pain sample, 0.9; non-cancer pain sample 1.4), and the majority 
of patients in both samples (cancer pain sample, 84%; non-cancer 
pain sample, 83%) reported wanting to have a BM at least once a 
day or more. Interestingly, the proportion of participants report-
ing PAC-SYM constipation symptoms at least moderate or more 
often tended to be higher among participants in the cancer pain 
cohort compared to those with non-cancer pain. Patients in the 
non-cancer cohort reported significantly longer durations of 
pain (mean ± SD years: non-cancer, 9.8 ± 8.9; cancer, 2.3 ± 3.6) 
and opioid use (mean ± SD years: non-cancer, 6.4 ± 6.3; cancer, 
1.3 ± 1.3), which may have contributed to this difference in results 
as the non-cancer pain patients have been coping with OIC for 
much longer and have developed a new “normal” with OIC.
Despite this considerable symptom burden, patients with 
cancer pain and OIC characterized their overall HRQL as slightly 
TaBle 6 | Benefit, satisfaction, and willingness to continue treatment.
Baseline 
(N = 31)
Have you had any benefit from your constipation  
treatment? N (%)
No 8 (25.8)
Yes 23 (74.2)
If yes, how much benefit? N (%)
Little benefit 13 (56.5)
Much benefit 10 (43.5)
Taking all things into account, are you satisfied with your 
constipation treatment? N (%)a
N = 30
No 10 (33.3)
If no, how dissatisfied? N (%)
A little dissatisfied 6 (60.0)
Very dissatisfied 4 (40.0)
Yes 20 (66.7)
If yes, how satisfied? N (%)
A little satisfied 8 (40.0)
Very satisfied 12 (60.0)
Would you be willing to continue constipation treatment with 
this medication? N (%)
No 1 (3.2)
If no, how unwilling? N (%)
A little unwilling 1 (100.0)
Very unwilling 0 (0.0)
Yes 30 (96.8)
If yes, how willing? N (%)
A little bit willing 6 (20.0)
Very willing 24 (80.0)
Missing 0 (0.0)
aDue to a problem with the programing of the survey, this question was not presented 
to one participant at baseline. The data are missing.
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better than those with non-cancer chronic pain (EQ-5D index 
0.54 cancer pain patients; 0.49 non-cancer pain; EQ-5D VAS 
cancer pain patients 54.4; non-cancer pain patients 50.4).
In terms of constipation-specific quality of life, participants 
with cancer pain in this study had PAC-QOL scores that were 
similar to those reported among patients with constipation and 
cancer pain in the DYONISOS study (4). As expected, these 
values were considerably higher, reflecting greater impairment 
in HRQL due to constipation, than those found in patients with 
cancer pain who do not suffer from constipation (4).
Taken together, these findings suggest that patients with 
cancer pain commonly experience burdensome constipation 
symptoms despite being more likely to proactively treat their 
OIC using sufficient laxatives as compared to patients with 
non-cancer pain. Previous publications evaluating laxative man-
agement in ambulatory cancer patients also suggest substantial 
unmet treatment needs (1). Wirz et al. (21) found that 53% of 
patients discontinued their laxative prescription in a prospective, 
open-label investigation of polyethylene glycol (PEG), sodium 
picosulphate, and lactulose. Importantly, Wirz et al. (21) found 
that those who stopped taking laxatives had significantly lower 
opioid doses – which could suggest that patients may compro-
mise their management of pain in order to avoid symptoms of 
constipation and the negative side effects resulting from available 
laxative treatment options as supported by Bell et al. (22). Indeed, 
43% (n = 12) of cancer pain patients in this study reported that 
OIC at least moderately interfered with their pain management.
Although most patients with cancer pain and OIC are  willing 
to continue their current laxative treatment regimen, there is 
a need for viable treatment alternatives with less burdensome 
side effect profiles and better efficacy. Novel peripherally acting 
μ-opioid antagonists may be useful in reversing opioid agonist-
induced actions, including bowel dysfunction (23).
There are a number of limitations to this study. First, as noted 
above, recruitment was prematurely terminated due to the dif-
ficulty encountered when recruiting sites and cancer patients with 
OIC. Reasons for recruitment difficulties were thought to be due 
to cancer pain patients being burdened with research and other 
treatment considerations, which reduced the likelihood and inter-
est to participate in non-interventional, observational research.
Thus, the small sample size (n = 31) is limited in its generaliz-
ability and precision with respect to point estimates on the charac-
teristics reported. The cohort is composed of patients with a range 
of different cancer diagnoses, levels of disease severity, and other 
health problems leaving this a descriptive analysis of the burden 
of OIC in a small number of cancer pain patients. Second, bowel 
habits in this study were not able to be compared to those prior to 
opioid use, so patients with a long-standing history of constipation 
could not be differentiated from those who had OIC. Third, the 
use of an Internet-based survey may have biased the study sample 
to those with higher levels of education and socioeconomic status. 
Finally, most of the study questions used a 1-week (7-day) recall 
period, which may have resulted in recall bias in reporting symp-
toms that vary from day to day. These limitations aside, the study 
does highlight the burden of OIC among patients with cancer pain.
cOnclUsiOn
Although most patients with cancer pain and OIC in this pre-
dominantly UK sample were willing to continue their current 
laxative treatment regimen, there appears to be a need for viable 
treatment alternatives with better efficacy. Further research 
on OIC burden and management of the condition is needed. 
To do so, challenges in recruiting sites and patients need to be 
elucidated and resolved, so that future research design for stud-
ies related to OIC in cancer pain can generate point estimates 
with acceptable precision. Increased awareness of OIC and its 
persistence among this already burdened patient cohort may be 
needed among HCPs.
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